Date | Company | Who recommends | Recommendation | Target price |
---|---|---|---|---|
Gilead Sciences Inc. | Deutsche Bank | Buy | 124 | |
HCA Holdings, Inc. | UBS | Buy | 90 | |
Humana Inc. | Barclays | Buy | 223 | |
Intuitive Surgical, Inc. | Barclays | Buy | 625 | |
Johnson & Johnson | Deutsche Bank | Buy | 105 | |
Mallinckrodt Public Limited Company | Barclays | Buy | 80 | |
Merck & Co. Inc. | UBS | Buy | 68 | |
Mylan N.V. | Barclays | Buy | 57 | |
PerkinElmer Inc. | UBS | Buy | 60 | |
Pfizer Inc. | Morgan Stanley | Buy | 43 | |
Regeneron Pharmaceuticals, Inc. | Barclays | Buy | 593 | |
St. Jude Medical Inc. | Deutsche Bank | Buy | 77 | |
Stryker Corporation | Argus | Buy | 120 | |
Thermo Fisher Scientific, Inc. | Argus | Buy | 145 | |
UnitedHealth Group Incorporated | Morgan Stanley | Buy | 140 | |
Universal Health Services Inc. | Barclays | Buy | 150 | |
Vertex Pharmaceuticals Incorporated | Argus | Buy | 155 | |
Waters Corporation | BofA/Merrill | Buy | 140 |